Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2202-2209

  Crews, Kristine R ^a   Stewart, Clinton F ^a   Jones Wallace, Dana ^a   Thompson, Stephen J ^a   Houghton, Peter J ^a   Heideman, Richard L ^a   Fouladi, Maryam ^a   Bowers, Daniel C ^b   Chintagumpala, Murali M ^c   Gajjar, Amar ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DEXAMETHASONE; DRUG METABOLITE; IRINOTECAN; LACTONE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR;

ADOLESCENT; ADULT; ANEMIA; ANTICONVULSANT THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG METABOLISM; FEMALE; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOKALEMIA; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; VOMITING; BRAIN TUMOR; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYME INDUCTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; COMPARATIVE STUDY; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; GLIOMA; HUMAN; INFUSIONS, INTRAVENOUS; MALE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS;

EID: 0035992361     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Therapeutic efficacy of the topoisomerase 1 inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts
2. Efficacy of oral irinotecan against neuroblastoma xenografts
3. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
4. Metabolism of irinotecan (CPT-II) by CYP3A4 and CYP3A5 in humans
5. 14]CPT-11 in cancer patients
6. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
7. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma
8. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in Phase II studies
9. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The new approaches to brain tumor therapy
10. Irinotecan therapy in adults with recurrent or progressive malignant glioma
11. Direct translation of a protracted irinotecan schedule from a xenograft model to a Phase I trial in children
12. A program package for simulation and parameter estimation in pharmacokinetic systems
13. Multicompartment models
14. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation
15. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia
16. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
17. Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes
18. Phenytoin causes a rapid increase in 6β-hydroxycortisol urinary excretion in humans: A putative measure of CYP3A induction
19. Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats
20. The expression of UDP-glucuronosyltransferases of the UGTI family in human liver and kidney and in response to drugs
21. The effects of inducing agents on cytochrome P450 and UDPglucuronyltransferase activities in human HEPG2 hepatoma cells
22. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
23. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGTIAI promoter polymorphism
24. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
25. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats
26. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications
27. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using nonsubstrate drugs or the BCRP inhibitor GF120918
28. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells
29. Possible involvement of P-glycoprotein in biliary excretion of CPT-II in rats
30. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells
31. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
32. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3)